NanoViricides, Inc. (NYSE American: NNVC) announced a registered direct offering expected to generate approximately $3.8 million in gross proceeds. The company entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 2,516,339 common shares, or pre-funded warrants in lieu thereof, together with warrants to purchase an equal number of common shares. Each full warrant has an exercise price of $1.75 per share and expires five and a half years after issuance. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions, with D. Boral Capital LLC serving as exclusive placement agent.
This capital infusion is critical for NanoViricides as it advances its lead drug candidate, NV-387, a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company is also developing NV-HHV-1 for shingles. NanoViricides is currently focused on moving NV-387 into Phase II human clinical trials. The company’s nanoviricide technology platform, based on intellectual property from TheraCour Pharma, Inc., aims to create special purpose nanomaterials for antiviral therapy.
The offering provides necessary working capital to support ongoing research and development, including preparations for clinical trials. NanoViricides has a broad pipeline targeting numerous viral diseases, including oral and genital herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola. The company holds exclusive perpetual licenses to TheraCour nanomedicine technology for several drugs targeting specific human viral diseases.
Investors should note the inherent risks in drug development, as there is no assurance that any of NanoViricides’ candidates will demonstrate sufficient effectiveness and safety for human clinical development or lead to a successful commercial product. The company’s ability to project exact timelines for regulatory filings depends on external collaborators and consultants.
For more details, the full press release is available at https://nnw.fm/2qH5W. Updates on NanoViricides can be found in the company’s newsroom at https://nnw.fm/NNVC.
